{"entity":{"id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","aka":[],"tldr":"A phase 1/2 trial of Sonrotoclax and Azacitidine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by BeOne Medicines, now recruiting.","summary":"A Study of BGB-11417 in Participants With Myeloid Malignancies is a phase 1/2 interventional study registered as NCT04771130 by BeOne Medicines, with 260 participants planned, started 2021-05-24 and due to reach its primary completion in 2028-08-31. Interventions recorded: BGB-11417, Azacitidine and Posaconazole.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04771130","url":"https://clinicaltrials.gov/study/NCT04771130"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["sonrotoclax","azacitidine"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04771130","phase":"1/2","setting":"A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies","sponsor":"BeOne Medicines","enrolled":260,"outcomes":[]},"route":"/trials/nct04771130/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}